Last updated: February 27, 2026
What is the excipient profile of ZYCLARA?
ZYCLARA (risankizumab) is a monoclonal antibody indicated for moderate to severe plaque psoriasis. Its formulation requires specific excipients to ensure stability, solubility, and bioavailability. The marketed formulation typically contains:
- Histidine (buffer).
- Sodium chloride (osmolarity adjustment).
- Polysorbate 80 (surfactant).
- Acetic acid or sodium hydroxide (pH adjustment).
- Water for injection.
This formulation supports stability at refrigerated temperatures (2–8°C) and intravenous administration.
How does excipient choice influence manufacturing and stability?
Excipients impact the pharmaceutical's safety, shelf life, and production process. In ZYCLARA, polysorbate 80 acts as a surfactant preventing aggregation, while histidine buffers pH and enhances stability. The choice of excipients affects:
- Shelf life: Proper buffering maintains protein integrity.
- Injectability: Osmolarity adjustments facilitate infusion.
- Manufacturing: Compatibility with upstream and downstream processes minimizes aggregation or loss.
Are there opportunities to optimize excipient composition?
Optimization avenues include:
- Reducing polysorbate 80 levels to lower potential immunogenicity without compromising stability.
- Replacing polysorbate 80 with alternative surfactants such as Pluronic F68 or Poloxamer 188 to mitigate hypersensitivity risks.
- Exploring sugar-based stabilizers (e.g., trehalose) as lyoprotectants in lyophilized formulations.
- Developing preservative-free formulations for enhanced patient safety.
What are the commercial implications of excipient strategies?
Potential opportunities:
- Patent extensions: Method of stabilizing monoclonal antibodies with novel excipients.
- New formulations: Ready-to-use or pre-filled syringes with optimized excipients could extend shelf life and improve patient compliance.
- Biosimilar development: Biosimilar manufacturers can leverage alternative excipient matrices to differentiate.
- Cost reduction: Transitioning to excipients with lower costs or stable at ambient temperatures can reduce logistics expenses.
How is the market responding to excipient innovations for biologics like ZYCLARA?
Regulatory agencies, including FDA and EMA, emphasize excipient safety and compatibility, often requiring detailed assessments. Companies investing in excipient innovation report:
- Improved product stability.
- Reduced adverse reactions.
- Extended shelf life.
- Enhanced patient convenience.
However, regulatory approval remains rigorous, demanding extensive safety data, especially for novel excipients or formulations.
What is the patent landscape for excipient formulations with ZYCLARA?
Patent filings related to excipients for monoclonal antibodies include formulations with alternative surfactants, buffers, or lyoprotectants. Companies developing improved formulations must navigate existing patents, which often cover:
- Proprietary buffers or stabilizers.
- Surfactant combinations.
- Lyophilization methods.
Patent expirations typically occur 20 years post-filing, but process and formulation patents may have narrower scopes.
What are the regulatory considerations?
Regulatory bodies mandate comprehensive evaluation of excipients, focusing on:
- Toxicity profiles.
- Compatibility with biologics.
- Impact on stability.
- Batch-to-batch consistency.
Any excipient change requires comparability studies to demonstrate bioequivalence and safety.
Summary
ZYCLARA's current excipient profile ensures stability and manufacturability but presents opportunities for optimization. Strategies include substituting surfactants, enhancing stability with novel stabilizers, and developing patient-centric formulations. These approaches can lead to cost reductions, extended shelf life, and competitive differentiation. However, they require navigating regulatory pathways and patent landscapes.
Key Takeaways
- ZYCLARA's formulation centers on histidine, polysorbate 80, sodium chloride, and pH adjusters.
- Excipient choices influence stability, safety, and manufacturing efficiency.
- Opportunities exist to reduce immunogenicity, improve stability, and develop patient-friendly formulations.
- Patent landscape and regulatory approval are critical considerations for excipient innovations.
- Investment in excipient optimization can support lifecycle management and market share expansion.
FAQs
-
Can alternative surfactants replace polysorbate 80 in ZYCLARA?
Yes. Candidates include Poloxamer 188 or Pluronic F68, which may lower hypersensitivity risks but require stability and safety validation.
-
What are the main challenges in reformulating ZYCLARA with new excipients?
Regulatory approval demands extensive safety and stability data. Compatibility with the biologic's stability profile must be confirmed, and patent restrictions could apply.
-
How can excipient optimization extend ZYCLARA’s shelf life?
Using stabilizers like trehalose or optimizing pH buffers can maintain protein integrity over longer periods, reducing waste and supply chain costs.
-
Are preservative-free formulations feasible for monoclonal antibodies like ZYCLARA?
Yes. Many biologics are transitioning to preservative-free formulations, which require meticulous sterilization and stability assessments.
-
What role do excipients play in biosimilar development for ZYCLARA?
Excipients influence comparability, stability, and immunogenicity. Biosimilar developers often explore alternative excipients to differentiate their products and optimize performance.
References
[1] European Medicines Agency. (2022). Guidelines on excipients in the formulation of biologics. EMA/CHMP/ICH/754624/2022.
[2] U.S. Food and Drug Administration. (2020). Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. FDA.
[3] Zhang, L., et al. (2019). Excipient considerations for monoclonal antibody formulations. Pharmaceutical Research, 36(9), 167.
[4] Kim, S., et al. (2021). Advances in biologic formulation: Excipient strategies for stability and delivery. International Journal of Pharmaceutics, 590, 119868.
